Allogreffe dans les syndromes myélodysplasiques
Bulletin du Cancer · 2023
DOI: 10.1016/j.bulcan.2023.02.025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bulletin du Cancer, 2023. Verfasst von Viviane Gournay und 1 weiteren Autor:innen. Beteiligte Einrichtung: AP-HP, université de Paris Cité, hôpital Saint-Louis, Paris, France. Electronic address: viviane.gournay@aphp.fr. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the treatment options for myelodysplastic syndromes (MDS). This treatment is indicated as first-line treatment for high-risk MDS according to the IPSS and R-IPSS classifications and improves overall survival and progression-free survival. However, allo-HSCT is not indicated in first intention for low-risk MDS. It can be discussed in case of cytopenias needing transfusions, poor evolution under other treatment, or in case of poor prognosis molecular anomaly. Allo-HSCT is a treatment that can be complicated by early or late toxicities (graft versus host disease, infections, chemotherapy toxicity…). The decision to do an allo-HSCT is based on the benefit/risk ratio between the risk of progression from MDS to myeloid leukemia and the risk of transplant related mortality, which increases with the patient's age and comorbidities. The indication of a cytoreductive treatment before allo-HSCT depends on the blasts count, and on the delay before the allograft. The use of reduced intensity conditioning regimen and alternative donors such as haploidentical donors, expanded the indications for allo-HSCT. Relapse remains one of the main causes of mortality after allo-HSCT. Some genetic mutations and karyotype anomalies increase the risk of post-transplant relapse. Preventive treatments for relapse are currently being studied. Treatments such as azacytidine, donor lymphocytes infusions or targeted therapies can be used, prophylactically or preemptively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- AP-HP, université de Paris Cité, hôpital Saint-Louis, Paris, France. Electronic address: viviane.gournay@aphp.fr.
- AP-HP, université de Paris Cité, hôpital Saint-Louis, Paris, France.
Zitieren
APA
Gournay, V., & Robin, M. (2023). Allogreffe dans les syndromes myélodysplasiques. Bulletin du Cancer. https://doi.org/10.1016/j.bulcan.2023.02.025
Vancouver
Gournay V, Robin M. Allogreffe dans les syndromes myélodysplasiques. Bulletin du Cancer. 2023. doi:10.1016/j.bulcan.2023.02.025
BibTeX
@article{Gournay2023,
author = {Gournay, Viviane and Robin, Marie},
title = {Allogreffe dans les syndromes myélodysplasiques},
journal = {Bulletin du Cancer},
year = {2023},
doi = {10.1016/j.bulcan.2023.02.025}
}
EUVIMED